Yelena Amitina, MD
Neurology · Forest Hills, NYNPI 1548380892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 49.3% of the total. Reporting peaked in 2023 at $180 and has fallen 88.5% since, to $21 in 2025. That places this record below the midpoint for neurology clinicians in NY, where the typical reported total is $913.
Across 25 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$264
- Amarin Pharma, Inc.$44
- Lilly USA, LLC$42
- Genentech USA, Inc.$32
- Medtronic$31
- Amgen$23
- plus $99 from 5 others
What the payments were for
- Food & beverage$536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $264 |
| Amarin Pharma, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Genentech USA, Inc. | 2 | $32 |
| Medtronic | 1 | $31 |
| Amgen | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Merck | 1 | $15 |
How this compares
$536 in reported general payments places this provider in the 40th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZelaparSelegiline Hcl | 13 | $33,771 |
| Gabapentin | 172 | $1,422 |
| Diclofenac Sodium | 50 | $1,020 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 26 | $451 |
| Tizanidine Hcl | 16 | $399 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $148 |
| Trazodone Hcl | 55 | $113 |
| Memantine Hcl | 16 | $111 |
| Citalopram HbrCitalopram Hydrobromide | 26 | $29 |
| Mirtazapine | 12 | $28 |
| Escitalopram Oxalate | 14 | $27 |
| Ropinirole Hcl | 14 | $24 |
| Meloxicam | 13 | $18 |
Paid to pharmacies, not to this prescriber.
Other neurology in Forest Hills
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.